Metagenomi, Inc. reported positive preclinical data for MGX-001, showing curative FVIII activity in non-human primates. Pre-IND meeting for MGX-001 expected in 4Q 2025 with IND/CTA submissions in 4Q 2026. Workforce reduced by 25% to extend cash runway into 4Q 2027. Jian Irish appointed CEO. Conference call today at 4:30 p.m. ET.

MGX-001 hemophilia A program demonstrated curative FVIII activity in non-human primates. Company focusing on MGX-001 program, secreted protein deficiencies, and cardiometabolic indications. Jian Irish promoted to CEO. Brian Thomas remains on Board. Dr. Willard Dere appointed as Board Chair. Cash, cash equivalents, and marketable securities at $184.1 million as of September 30, 2025.

Metagenomi strategically evolved pipeline to focus on MGX-001 hemophilia A program and other key projects. Workforce reduced by 25%. Jian Irish appointed CEO. Financial results showed R&D expenses at $25.3 million and G&A expenses at $6.2 million for the quarter ended September 30, 2025. Cash position supports operations until 4Q 2027.

Metagenomi to host conference call today at 4:30 p.m. ET to discuss MGX-001 preclinical results and business updates. MGX-001 program aims to provide lifelong protection for hemophilia A patients. Company focusing on developing genetic medicines for various diseases. Jian Irish appointed as CEO. Cash runway extended until 4Q 2027.

Read more at GlobeNewswire: Metagenomi Reports Third Quarter 2025 Financial Results and